U.S., Sept. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07844148) titled 'A Study to Compare GNR-139 and Eylea(R) in Patients With nAMD' on Sept. 18.
Brief Summary: This is a multicenter, randomized, double-blind study designed to compare the efficacy and safety of the investigational drug GNR-139 with the reference drug Eylea in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Participants will be randomly assigned to receive either GNR-139 or Eylea. Neither the participants nor the study doctors will know which treatment is being administered. Both drugs will be given as an intravitreal injection dose of 8 mg (0.07 mL at a concentration of 114.3 mg/mL).
Patients meet...